Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Forgber, Michael ^a   Gellrich, Sylke ^a   Sharav, Tumenjargal ^a   Sterry, Wolfram ^a   Walden, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME; TUMOR ANTIGEN; VIMENTIN;

ANTIGEN DETECTION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREACTIVITY; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYCOSIS FUNGOIDES; PROTEIN DETERMINATION; SEROLOGY; SKIN LYMPHOMA; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; LYMPHOMA; MYCOSIS FUNGOIDES; PROTEOME; SEROLOGIC TESTS; SKIN NEOPLASMS;

EID: 77949504581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008376     Document Type: Article

References (59)

1. Huang S, Preuss KD, Xie X, et al. (2002) Analysis of the antibody repertoire of lymphoma patients. Cancer Immunol Immunother 51: 655-662.
2. Sahin U, Tureci O, Schmitt H, et al. (1095) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813.
3. Mobley JA, Lam YW, Lau KM, Pais VM, L'Esperance JO, et al. (2004) Monitoring the serological proteome: the latest modality in prostate cancer detection. J Urol 172: 331-337.
4. Klemke CD, Goerdt S, Schrama D, Becker JC (2006) New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges 4: 395-406.
5. Morra E (1999) The biological markers of non-Hodgkin's lymphomas: their role in diagnosis; prognostic assessment and therapeutic strategy. Int J Biol Markers 14: 149-153.
6. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M (2002) Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 188: 43-50.
7. Kersten C, Delabie J, Gaudernack G, Smeland EB, Fossa A (2004) Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2. Cancer Immunol Immunother 53: 1119-1126.
8. Hassel JC, Meier R, Joller-Jemelka H, Burg G, Dummer R (2004) Serological immunomarkers in cutaneous T cell lymphoma. Dermatology 209: 296-300.
9. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, et al. (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 98: 629-634.
10. Theinert SM, Pronest MM, Peris K, Sterry W, Walden P (2005) Identification of the testis-specific protein 10(TSGA10) as serologically defined tumour- associated antigen in primary cutaneous T-cell lymphoma. Br J Dermatol 153: 639-641.
11. Jager D, Stockert E, Jager E, Gure AO, Scanlan MJ, et al. (2000) Serological cloning of a melanocyte rab guanosine 59-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. Cancer Res 60: 3584-3591.
12. Liggins AP, Guinn BA, Banham AH (2005) Identification of lymphoma- associated antigens using SEREX. Methods Mol Med 115: 109-128.
13. Hishizawa M, Imada K, Sakai T, Ueda M, Uchiyama T (2005) Identification of APOBEC3B as a potential target for the graft-versus-lymphoma effect by SEREX in a patient with mantle cell lymphoma. Br J Haematol 130: 418-421.
14. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, et al. (2002) Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100: 2123-2131.
15. Hartmann TB, Bazhin AV, Schadendorf D, Eichmuller SB (2005) SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer 114: 88-93.
16. Liggins AP, Brown PJ, Asker K, Pulford K, Banham AH (2004) A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. Br J Cancer 91: 141-149.
17. Liggins AP, Guinn BA, Hatton CS, Pulford K, Banham AH (2004) Serologic detection of diffuse large B-cell lymphoma-associated antigens. Int J Cancer 110: 563-569.
18. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, et al. (1998) Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95: 6919-6923.
19. S. Towards defining specific antigens for cutaneous lymphomas. Onkologie 25: 448-454.
20. Eichmuller S, Usener D, Thiel D, Schadendorf D (2003) Tumour-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. Int J Cancer 104: 482-487.
21. Hartmann TB, Thiel D, Dummer R, Schadendorf D, Eichmuller S (2004) SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol 150: 252-258.
22. D, Schadendorf D, Koch J, Dubel S, Eichmuller S (2993) cTAGE: a cutaneous T cell lymphoma associated antigen family with tumour-specific splicing. J Invest Dermatol 121: 198-206.
23. Lee M, Kistler C, Hartmann TB, Li F, Dummer R, et al. (2007) Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins. Cancer Immunol Immunother 56: 783-795.
24. Hartmann TB, Mattern E, Wiedemann N, van Doorn R, Willemze R, et al. (2008) Identification of selectively expressed genes and antigens in CTCL. Exp Dermatol 17: 324-334.
25. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768-3785.
26. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, et al. (2007) ISCL/ EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110: 1713-1722.
27. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, et al. (2003) Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3: 45-55.
28. Shoshan SH, Admon A (2007) Novel technologies for cancer biomarker discovery: humoral proteomics. Cancer Biomark 3: 141-152.
29. Philip R, Murthy S, Krakover J, Sinnathamby G, Zerfass J, et al. (2007) Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res 6: 2509-2517.
30. Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, et al. (2007) Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res 6: 4025-4031.
31. Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M (2007) Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 1107: 223-230.
32. Kellner R, Lichtenfels R, Atkins D, Bukur J, Ackermann A, et al. (2002) Targeting of tumor associated antigens in renal cell carcinoma using proteome- based analysis and their clinical significance. Proteomics 2: 1743-1751.
33. Caron M, Choquet-Kastylevsky G, Joubert-Caron R (2007) Cancer immu- nomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 6: 1115-1122.
34. Uhlen M, Ponten F (2005) Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 4: 384-393.
35. Huguet S, Labas V, Duclos-Vallee JC, Bruneel A, Vinh J, et al. (2004) Heterogeneous nuclear ribonucleoprotein A2/B1 identified as an autoantigen in autoimmune hepatitis by proteome analysis. Proteomics 4: 1341-1345.
36. M, Trefzer U, Sterry W, Walden P (2009) Proteome serological determination of tumor-associated antigens in melanoma. PloS One: in press.
37. Krah A, Jungblut PR (2004) Immunoproteomics. Methods Mol Med 94: 19-32.
38. Bacarese-Hamilton T, Bistoni F, Crisanti A (2002) Protein microarrays: from serodiagnosis to whole proteome scale analysis of the immune response against pathogenic microorganisms. Biotechniques Suppl: pp 24-29.
39. Jungblut PR, Bumann D (2002) Immunoproteome of Helicobacter pylori. Methods Enzymol 358: 307-316.
40. Forgber M, Basu R, Roychoudhury K, Theinert S, Roy S, et al. (2006) Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS One 1: e40.
41. Linnemann T, Tumenjargal S, Gellrich S, Wiesmuller K, Kaltoft K, et al. (2001) Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol 31: 156-165.
42. Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen PB, et al. (1992) Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 28A: 161-167.
43. Gorg A, Postel W, Gunther S (1988) The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 9: 531-546.
44. Chan C, Warlow RS, Chapuis PH, Newland RC, Bokey EL (1999) Immobiline- based two-dimensional gel electrophoresis: an optimised protocol for resolution of human colonic mucosal proteins. Electrophoresis 20: 3467-3471.
45. Blum H, Beier H, Gross HJ (1987) Improved silver staining of plant proteins; RNA and DNA in polyacrylamide gels. Electrophoresis 8: 93-99.
46. Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM (1999) Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis 20: 601-605.
47. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, et al. (2003) Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEO- MEX analyses. Biochim Biophys Acta 1646: 21-31.
48. Craven RA, Stanley AJ, Hanrahan S, Dods J, Unwin R, et al. (2006) Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 6: 2853-2864.
49. Gunawardana CG, Diamandis EP (2007) High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 249: 110-119.
50. L, Sanvito F, Olivieri S, Vigano F, Doglioni C, et al. (2008) Serological immunoreactivity against colon cancer proteome varies upon disease progression. J Proteome Res 7: 504-514.
51. Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, et al. (2008) Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 7: 4004-4012.
52. Li C, Tan YX, Zhou H, Ding SJ, Li SJ, et al. (2005) Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics 5: 1125-1139.
53. Li C, Xiao Z, Chen Z, Zhang X, Li J, et al. (2006) Proteome analysis of human lung squamous carcinoma. Proteomics 6: 547-558.
54. Yang F, Xiao ZQ, Zhang XZ, Li C, Zhang PF, et al. (2007) Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 6: 751-758.
55. Cui JW, Li WH, Wang J, Li AL, Li HY, et al. (2005) Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4: 1718-1724.
56. Gure AO, Stockert E, Arden KC, Boyer AD, Viars CS, et al. (2000) CT10, a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer 1285: 726-732.
57. Modarressi MH, Cameron J, Taylor KE, et al. (2001) Identification and characterisation of a novel gene; TSGA10; expressed in testis. Gene 262: 249-255.
58. Tanaka R, Ono T, Sato S, et al. (2004) Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity. Microbiol Immunol 48: 339-345.
59. Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee HG, et al. (2004) Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother 53: 589-599.